PATENT CLAIM ANALYSIS

Application Number: 16012180
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["435", "006120"]

Abstract:
Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an FBW7 mutation or other FBW7 deficiency are sensitive to Mc11 inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit Mc11. Some embodiments provide methods of treating a proliferative disease based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of classifying a hyperproliferative cell or cell population, for example, a malignant cell or cell population based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of selecting a treatment regimen for treating a proliferative disease, for example, a malignant disorder, based on an assessment of FBW7 expression level or mutation status.

Claim (Index 49):
The method of  claim 48 , wherein the point mutation is a G423V mutation, a R456C mutation, a R456H mutation, a R479L mutation, a R479Q mutation, a R505C mutation, or a D527G mutation.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 2.37931
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14001970', '14354822', '14386747', '14713379', '13133883']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5131893271549476
- 35 USC 102 Novelty (BERT): 0.5579541377561589
- Combined Prediction Score: 0.5176658082150687
- Mean Citation Score: 232.813488
- Max Citation Score: 436.96695
- Similarity Product: 291.11458883423217

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test